troglitazone has been researched along with Renal Insufficiency in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ogawa, M | 1 |
Hirawa, N | 1 |
Tsuchida, T | 1 |
Eguchi, N | 1 |
Kawabata, Y | 1 |
Numabe, A | 1 |
Negoro, H | 1 |
Hakamada-Taguchi, R | 1 |
Seiki, K | 1 |
Umemura, S | 1 |
Urade, Y | 1 |
Uehara, Y | 1 |
1 other study available for troglitazone and Renal Insufficiency
Article | Year |
---|---|
Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hypoglycemic Agents; Immunoenz | 2006 |